SEC Form 4 · accession 0001209191-19-011079

Karyopharm Therapeutics Inc. · KPTI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CSO

Period of report

Feb 15, 2019

Accepted (ET)

Feb 19, 2019 · 4:25 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001503802

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F1	$9.21	Feb 15, 2019	A	231,200	A	—	Feb 14, 2029	Common Stock	231,200	231,200	D
Stock Option (right to buy)^F1	$9.21	Feb 15, 2019	A	231,200	A	—	Feb 14, 2029	Common Stock	231,200	231,200	I
Restricted Stock Units^F2,F3	—	Feb 15, 2019	A	87,200	A	—	—	Common Stock	87,200	87,200	D
Restricted Stock Units^F2,F4	—	Feb 15, 2019	A	87,200	A	—	—	Common Stock	87,200	87,200	I

F1This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.
F3The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.
F4The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.